Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B51f76b8d7dd8c836ef4a3a76ac72962c> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B51f76b8d7dd8c836ef4a3a76ac72962c NCIT_P378 "NCI" @default.
- B51f76b8d7dd8c836ef4a3a76ac72962c type Axiom @default.
- B51f76b8d7dd8c836ef4a3a76ac72962c annotatedProperty IAO_0000115 @default.
- B51f76b8d7dd8c836ef4a3a76ac72962c annotatedSource NCIT_C170914 @default.
- B51f76b8d7dd8c836ef4a3a76ac72962c annotatedTarget "A preparation of autologous T-lymphocytes transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, and electroporated with clustered regularly interspaced short palindromic repeats (CRISPR) guide RNA to disrupt expression of endogenous hematopoietic progenitor kinase 1 (HPK1), with potential immunostimulating and antineoplastic activities. Upon introduction into the patient, the autologous CRISPR-edited anti-CD19 CAR T-cells XYF19 recognize and bind to CD19-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD19-positive tumor cells. Disrupting the expression of HPK1 may enhance immune response and autoimmunity. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. HPK1 is a Ste20-like serine/threonine kinase that suppresses immune responses and autoimmunity." @default.